ROLLINS, INC. (ROL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $36.38, ROLLINS, INC. (ROL) is priced for +15.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-08.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/ROL

Headline

FieldValue
TickerROL
CompanyROLLINS, INC.
Sector / IndustryIndustrials
Current price$36.38/sh
CompositionResidential revenues 45% / Commercial revenues 33% / Termite and ancillary revenues 21% / Franchise revenues 0% / Other revenues 1%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)5.3%
Operating margin today18.7%
Margin compression (value-band)-13.4pp
Implied growth15.7%
Multiple paid25x operating income

The operating-margin figure is value-band context at year 11: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.2% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history+0.23σ
cohort percentile (of 225 peers)68

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.04x5expensive
Earnings3.08x5expensive
Relative1.95x5expensive
Growth1.12x3expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.7%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$32.491.12xyesFCF base $0.6B, growth 10% (input: historical growth), terminal g 4.0%, WACC 8.7%, 6yr projection
DCF Exit MultipleGrowth$40.390.90xyesExit EV/EBITDA: 22.2x / 24.2x / 26.2x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$25.111.45xyesP/E 22.48x (blended: static sector reference 18x + trailing (TTM) 33x), scenarios: 18.7x / 22.5x / 26.2x (bear / base = reference held flat / bull), EV/EBITDA 15.66x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$11.953.04xyesBV/sh $2.97, ROE (TTM) 37.2%, ke 9.3%
Two-Stage Excess ReturnAsset$26.021.40xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$32.581.12xyesRev $3.9B, growth 10% (input: historical growth; tapered), Terminal P/S: 3.7x / 4.5x / 5.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$13.202.76xyesEPS $1.10, growth 11% (input: historical EPS growth), PEG=2.91 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$9.054.02xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.61B × (1−24%) / WACC 8.7% → EPV (no growth)
Residual IncomeAsset$18.761.94xyesBV $2.97 + 5yr PV of (ROE (TTM) 37.2% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$8.584.24xyes√(22.5 × EPS $1.10 × BVPS $2.97) — Graham's conservative floor
EV/EBITDA RelativeRelative$16.972.14xyesEBITDA $0.76B × sector EV/EBITDA 12.0x
FCF YieldEarnings$11.823.08xyesFCF $619.2M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$10.893.34xyesSBC-adj FCF $0.58B (FCF $0.62B − SBC $0.04B) capitalized at Kₑ
Ben Graham FormulaEarnings$28.711.27xyesEPS $1.10 × (8.5 + 2×11.3%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$2.1317.08xyesBV $2.97 × (ROIC 6.3% / WACC 8.7%)
P/Sales SectorRelative$20.391.78xyesRevenue $3.92B × sector P/S 2.5x
PEG Fair ValueRelative$18.681.95xyesEPS $1.10 × (PEG 1.5 × growth 11.3% (input: historical EPS growth)) → PE 17.0x
Earnings YieldEarnings$11.893.06xyesEPS $1.10 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Pest and termite control (single reportable segment)operatingenterprise3.8B reported-currencywithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$593.9m
Net debt / NOPAT (after-tax)1.07x
Net debt / operating income (pre-tax)0.81x
Interest coverage21.8x
Share count CAGR (buyback)-0.6%
Burning cashno

Peer Cohorts (Per Segment, With Filing Citations)

Pest and termite control (single reportable segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ROL report on boothcheck